Zanetti A R, Mannucci P M, Tanzi E, Moroni G A, De Paschale M, Morfini M, Carnelli V, Tirindelli M C, De Biasi R, Ciavarella N
Am J Hematol. 1986 Dec;23(4):339-45. doi: 10.1002/ajh.2830230406.
One-hundred thirteen adults and children with hemophilia or other congenital bleeding disorders were vaccinated against the hepatitis B virus. Each patient was given three subcutaneous injections of the vaccine at monthly intervals and then a fourth booster dose 14 months after the first. The vaccine was highly immunogenic, since 111 of 113 patients (98%) produced anti-HBs (10 mIU/ml or more). After the first three vaccine doses and after the booster dose, ten anti-LAV/HTLV-III-positive hemophiliacs produced anti-HBs but had a lower average titer than anti-LAV/HTLV-III-negative hemophiliacs. Of the 23 patients treated with concentrates in the 15 month postvaccination period only, none acquired HBV infection. Of the 50 patients treated with concentrates also in the 6 month prevaccination period, one developed hepatitis B. In summary, the vaccine was highly immunogenic in both children and adults with hemophilia; anti-LAV/HTLV-III-positive patients responded to the vaccine, but the average anti-HBs response was lower; no case of hepatitis B occurred in patients treated with concentrates only in the postvaccination period.
113名患有血友病或其他先天性出血性疾病的成人及儿童接种了乙肝疫苗。每位患者每月接受三次皮下注射疫苗，之后在首次注射14个月后进行第四次加强剂量注射。该疫苗具有高度免疫原性，因为113名患者中有111名（98%）产生了抗-HBs（10 mIU/ml或更高）。在前三剂疫苗及加强剂量之后，10名抗-LAV/HTLV-III阳性的血友病患者产生了抗-HBs，但平均滴度低于抗-LAV/HTLV-III阴性的血友病患者。仅在接种疫苗后15个月内接受浓缩物治疗的23名患者中，无人感染HBV。在接种疫苗前6个月也接受浓缩物治疗的50名患者中，有1人患上了乙型肝炎。总之，该疫苗在患有血友病的儿童和成人中均具有高度免疫原性；抗-LAV/HTLV-III阳性患者对疫苗有反应，但抗-HBs平均反应较低；仅在接种疫苗后接受浓缩物治疗的患者中未出现乙型肝炎病例。
